SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is trending as community members highlight bullish price action and speculate about future growth potential. Conversations mention the potential for significant gains and the coin's strong community support. Some users are drawing comparisons to other meme coins on Solana, suggesting a broader interest in the sector.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies around the Solana-based meme token and its unique branding, highlighted by the playful "What's UpDog?" catchphrase. Community members are actively celebrating $UPDOG.X's presence on the Jupiter Strict List and its resilient, long-term development within the memecoin sector.

TOSHI

TOSHI.X is trending as the community rallies around the meme coin, anticipating significant gains and a potential Binance listing soon. Bullish sentiment is fueled by recent listings, the coin's association with Coinbase, and its status as the 'face of base'. Traders are closely watching for a breakout, with some suggesting a coordinated buy to propel the price higher.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community anticipates upcoming revenue figures and discusses treasury mechanics.  Enthusiasm is building around its real-world asset (RWA) adoption and potential for significant growth. Some users are also discussing potential integrations with other tokens.

Nyvo is a cutting-edge platform that allows anyone to create fully functional decentralized applications (dApps) using simple natural language prompts. In other words, users describe the app they want in plain English, and Nyvo’s AI-driven engine automatically generates both the on-chain smart contract backend and the web-based frontend, delivering a live blockchain application within minutes. This “prompt-to-dApp” approach dramatically lowers the barriers to Web3 development by removing the need to write code or navigate complex developer tools.The result is that developers, entrepreneurs, and even non-technical users can go from an idea to a deployed dApp faster and easier than ever before.

Nyvo

Nyvo ($NYVO.X) is trending as social media buzz points to strong chart momentum and a potential breakout. The crypto community is signaling a 'buy now' opportunity, anticipating a rapid price increase. Conversations evoke a sense of urgency, suggesting a 'rocket' is about to launch.

Inspired by the vote-escrow model from Curve and the anti-dilution mechanism from Olympus, veTHE holders control 100% of Thena’s emissions allocated to gauges and benefit from weekly rebases, reducing dilution from emissions over time. THE Model rewards long-term supporters, and aligns stakeholders interests by incentivizing fee generation.

The Protocol

$THE.X is trending as community members discuss a recent listing on Gate.io and speculate on upcoming exchange listings. Many are drawing comparisons to other meme coins like $SHIB.X and $DOGE.X, while also pointing to a possible connection to Vitalik Buterin.

Mamo turns what used to be complex into easy, human-first routines.  It works quietly in the background, finding smart opportunities for your money while you focus on what matters in your life. Think of Mamo as your knowledgeable friend who understands how to help your money grow and explain everything in plain language.  Behind the scenes, Mamo applies proven strategies and real-time data to optimize your portfolio, reinvest earnings when conditions are right, and adapt to market shifts — all with your approval and full transparency.  No noise. No confusion. Just calm, steady growth.

Mamo

MAMO.X is trending as community members discuss its potential integration with the Base App and speculate on future price targets. Many are also comparing it to other cryptocurrencies, while highlighting its utility and low market cap. The potential Coinbase listing is also fueling excitement.

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Cullinan Therapeutics Inc

Cullinan Oncology Inc

Cullinan Oncology is trending due to analyst upgrades and upcoming presentations at the ASCO and other medical conferences, highlighting data related to their cancer treatment pipeline. Community members are actively discussing the company's valuation, pipeline potential, and recent insider trading activity. A recent analysis comparing CGEM to a competitor, BDTX, is also circulating.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending as a new board has been created on the platform after significant after-hours movement. The community is discussing the company's recent activity and deal terms, including potential dilution from warrants with no lock-up period. There is also discussion about the listing and proper display of the ticker on the platform.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI.X is trending as the community emphasizes its significance as the 'meme version of Bitcoin' and a tribute to the creator of crypto. Many believe $SATOSHI.X represents the identity of the entire crypto industry and embodies a movement, with the phrase 'We are all Satoshi' frequently used. Discussions also highlight the limited supply and potential for significant growth, drawing comparisons to early Bitcoin days.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Allakos, Inc. shares lost more than three-quarters of its market capitalization on Tuesday afternoon, marking a record low after the company announced a significant setback for its lead drug candidate, AK006.The biotech company revealed it would cease further clinical development of AK006 after its preclinical inhibitory effects failed to translate into clinical benefits for patients with chronic spontaneous urticaria (CSU).In the proof-of-concept trial, 34 adult patients with moderate-to-severe CSU refractory to antihistamines, with or without prior omalizumab exposure, were randomized 2:1 to receive AK006 or placebo.&nbsp;The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.&nbsp;The company will retain a small team of about 15 employees to explore strategic alternatives, ensure compliance, and oversee the wind-down of its phase 1 trial.Allakos ended the fourth quarter of 2024 with $81 million in cash and expects restructuring costs of $34–$38 million, primarily to be paid by mid-2025.&nbsp;The company estimates its cash reserves will decline to $35–$40 million by June 30, 2025.Following the announcement, several analysts adjusted their outlook on Allakos, according to The Fly.Piper Sandler downgraded the stock to ‘Neutral’ from ‘Overweight,’ slashing its price target to $0.30 from $7. The brokerage noted AK006 was Allakos’s sole asset, leaving the remaining valuation restricted to cash.JMP Securities downgraded Allakos to ‘Market Perform’ from ‘Outperform’.On Stocktwits, sentiment for Allakos shifted sharply to ‘bearish’ as disappointed retail investors voiced their concerns.&nbsp;<stembedurl>https://stocktwits.com/Majlo97/message/601635808</stembedurl><stembedurl>https://stocktwits.com/subieroo_wrx/message/601634053</stembedurl>Data showed declining interest in the stock, with a 4.6% drop in followers over the past year and a 44% reduction in message volume last week.<a href="https://stocktwits.com/symbol/ALLK">Allakos stock</a> has now lost 77% over the past 12 months, reflecting mounting challenges for the small-cap biotech as it faces an uncertain future.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade

The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.

Equity

Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm PR Newswire NEW YORK, Dec. 19, 2024 NEW YORK, Dec. 19, 2024...

Leerink Partnrs Research Analysts Lower Earnings Estimates for Allakos Inc. (NASDAQ:ALLK)

Allakos Inc. (NASDAQ:ALLK  Free Report)  Equities researchers at Leerink Partnrs decreased their FY2025 EPS estimates for shares of Allakos in a research report issued to clients and...

Short Interest in Allakos Inc. (NASDAQ:ALLK) Increases By 9.1%

Allakos Inc. (NASDAQ:ALLK  Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 29th, there was short interest totalling...

Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4

Restructuring Plan Aims to Extend Cash Runway Amid Clinical Development FocusRelated Stocks: ALLK...

Allakos says restructuring extends cash runway into mid-2026

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Allakos reports Q4 EPS (71c), consensus (47c)

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company ) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...

Commit To Buy Allakos At $1, Earn 17.9% Annualized Using Options

Investors eyeing a purchase of Allakos Inc (ALLK) shares, but cautious about paying the going market price of 1.48/share, might benefit from considering selling puts among the alternative...

Allakos Inc. (NASDAQ:ALLK) Given Average Rating of "Hold" by Analysts

Shares of Allakos Inc. (NASDAQ:ALLK  Get Free Report) have earned an average rating of Hold from the seven analysts that are currently covering the company, MarketBeat Ratings...

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Allakos Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$0.3291
Prev Close	$0.3293
Open	$0.3283
Dividend Yield	0.00%
50-Day Moving Average	$0.3035
Beta	1.77
Avg. Volume	2.08M
PE Ratio	-0.41

52-Week High	$1.56
52-Week Low	$0.2157
Market Capitalization	$29.74M
EPS (Annual)	-$1.30
Price to Book	0.54
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ALLK
Allakos Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALLK News

ALLK Allakos Inc